Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced October-November 2014.
PDI Inc. acquired molecular diagnostics company RedPath Integrated Pathology Inc. PDI paid $12mm up front and issued to RedPath shareholders an $11mm non-interest-bearing four-year subordinated note (to be paid in eight equal installments beginning in October 2016). (Nov.)
PDI will incorporate RedPath into its Interpace Diagnostics LLC division, with RedPath eventually taking the Interpace name but retaining...
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.
Joshi joins the parent company of Citeline, which houses flagship publications In Vivo, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.
